Human platelet glycoprotein V (GP5) is a part of the Ib-V-IX system of surface glycoproteins that constitute the receptor for von Willebrand factor (VWF; MIM 613160) and mediate the adhesion of platelets to injured vascular surfaces in the arterial circulation, a critical initiating event in hemostasis. The main portion of the receptor is a heterodimer composed of 2 polypeptide chains, an alpha chain (GP1BA; MIM 606672) and a beta chain (GP1BB; MIM 138720), that are linked by disulfide bonds. The complete receptor complex includes noncovalent association of the alpha and beta subunits with platelet glycoprotein IX (GP9; MIM 173515) and GP5. Mutations in GP1BA, GP1BB, and GP9 have been shown to cause Bernard-Soulier syndrome (MIM 231200), a bleeding disorder (review by Lopez et al., 1998 [PubMed 9616133]).[supplied by OMIM, Nov 2010]
Forensic Context
A study in human trauma patients demonstrated that the GP5 mRNA was significantly downregulated in circulating T cells during the injury stage compared to the recovery stage [Rau et al. DOI:10.2147/JIR.S375881]. In a separate human study on acute myocardial infarction, the GP5 gene was identified as upregulated at 7 days post-event, where it helps assess platelet activation and serves as a potential therapeutic target for improving haemostasis [Wang et al. DOI:10.1038/s41598-024-60945-3].